EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals

Ana María López-Estévez iD, Philipp Lapuhs iD, Laura Pineiro-Alonso iD, María José Alonso iD

Advanced Materials · 2024-04 · 36 (14)

DOI: 10.1002/adma.202309355 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 31.12.2023. Verfasst von Ana María López-Estévez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), Department of Pha…. Hauptthemen laut MEDLINE: Neoplasms, Biological Products, Nanoparticles. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 267 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Universidades, Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The success of personalized medicine in oncology relies on using highly effective and precise therapeutic modalities such as small interfering RNA (siRNA) and monoclonal antibodies (mAbs). Unfortunately, the clinical exploitation of these biological drugs has encountered obstacles in overcoming intricate biological barriers. Drug delivery technologies represent a plausible strategy to overcome such barriers, ultimately facilitating the access to intracellular domains. Here, an overview of the current landscape on how nanotechnology has dealt with protein corona phenomena as a first and determinant biological barrier is presented. This continues with the analysis of strategies facilitating access to the tumor, along with conceivable methods for enhanced tumor penetration. As a final step, the cellular barriers that nanocarriers must confront in order for their biological cargo to reach their target are deeply analyzed. This review concludes with a critical analysis and future perspectives of the translational advances in personalized oncological nanomedicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsBiological ProductsNanoparticlesHumansNanomedicineDrug Delivery SystemsNanotechnologyRNA, Small Interfering

Stichwörter der Autor:innen

RNAcancerintracellularmonoclonal antibodynanotechnology

Substanzen

RNA, Small InterferingBiological Products

Autor:innen und Institutionen

  • Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Health Research Institute of Santiago de Compostela (IDIS), Department of Pharmacology, Pharmaceutics and Pharmaceutical Technology, School of Phar…

ORCID-Profile: Ana María López-Estévez, Philipp Lapuhs, Laura Pineiro-Alonso, María José Alonso

Förderung

  • Ministerio de Universidades
  • Ministerio de Ciencia e Innovación
  • Instituto de Salud Carlos III
  • Ministerio de Ciencia, Innovación y Universidades
  • Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia
  • Xunta de Galicia

Zitieren

APA

López-Estévez, A. M., Lapuhs, P., Pineiro-Alonso, L., & Alonso, M. J. (2024). Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals. Advanced Materials, 36(14). https://doi.org/10.1002/adma.202309355

Vancouver

López-Estévez AM, Lapuhs P, Pineiro-Alonso L, Alonso MJ. Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals. Advanced Materials. 2024;36(14). doi:10.1002/adma.202309355

BibTeX
@article{LpezEstvez2024,
  author = {López-Estévez, Ana María and Lapuhs, Philipp and Pineiro-Alonso, Laura and Alonso, María José},
  title = {Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {14},
  doi = {10.1002/adma.202309355}
}
Kostenlos starten →